A Study Evaluating MM-310 in Patients With Solid Tumors
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on
cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1
open-label study of MM-310 in patients with solid tumors. In the first part of the study,
MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established.
After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in
combination with other therapies will be assessed.